Target Price | $16.32 |
Price | $5.41 |
Potential |
201.66%
register free of charge
|
Number of Estimates | 9 |
9 Analysts have issued a price target Vir Biotechnology Inc 2026 .
The average Vir Biotechnology Inc target price is $16.32.
This is
201.66%
register free of charge
$32.55
501.66%
register free of charge
$12.12
124.03%
register free of charge
|
|
A rating was issued by 13 analysts: 10 Analysts recommend Vir Biotechnology Inc to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Vir Biotechnology Inc stock has an average upside potential 2026 of
201.66%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 74.21 | 16.54 |
13.89% | 77.72% | |
EBITDA Margin | -743.66% | -3,210.26% |
6.28% | 331.68% | |
Net Margin | -703.36% | -2,700.60% |
1.45% | 283.96% |
10 Analysts have issued a sales forecast Vir Biotechnology Inc 2025 . The average Vir Biotechnology Inc sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Vir Biotechnology Inc EBITDA forecast 2025. The average Vir Biotechnology Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Vir Biotechnology Inc Analysts have issued a net profit forecast 2025. The average Vir Biotechnology Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -3.83 | -3.23 |
16.56% | 15.67% | |
P/E | negative | |
EV/Sales | negative |
10 Analysts have issued a Vir Biotechnology Inc forecast for earnings per share. The average Vir Biotechnology Inc EPS is
This results in the following potential growth metrics and future valuations:
Vir Biotechnology Inc...
Analyst | Rating | Action | Date |
---|---|---|---|
Needham |
Locked
➜
Locked
|
Locked | May 22 2025 |
Needham |
Locked
➜
Locked
|
Locked | May 12 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
Barclays |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
Needham |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 31 2025 |
Analyst Rating | Date |
---|---|
Locked
Needham:
Locked
➜
Locked
|
May 22 2025 |
Locked
Needham:
Locked
➜
Locked
|
May 12 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
Barclays:
Locked
➜
Locked
|
Feb 28 2025 |
Locked
Needham:
Locked
➜
Locked
|
Feb 27 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 31 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.